JonesResearch lowered the firm’s price target on Day One Biopharmaceuticals (DAWN) to $34 from $39 and keeps a Buy rating on the shares. The firm says it corrected the company’s collaboration revenue line for 2025 and onwards that was incorrectly linked to 2024. It also fine-tuned its Q4 revenue number for an estimated adjusted peak revenue of $1.2B in 2033 for Ojemda in pediatric low grade glioma.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Biopharmaceuticals Announces Leadership Transition
- Day One Biopharmaceuticals management to meet with Piper Sandler
- Day One Biopharmaceuticals’ Revenue at Risk: Heavy Dependence on Few Key Customers
- Day One Biopharmaceuticals Reports Strong Q3 Growth
- Closing Bell Movers: Microsoft, Meta both down about 3% despite earnings beats